EXO 226

Drug Profile

EXO 226

Latest Information Update: 14 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exocell
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetic nephropathies

Most Recent Events

  • 14 May 2003 No development reported - Phase-III for Diabetic nephropathies in USA (PO)
  • 05 Jan 2001 EXO 226 is available for licensing (http://www.exocell.com)
  • 23 Aug 1999 Phase-III clinical trials for Diabetic nephropathies in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top